About 31 results found for searched term "PRIMA-1" (0.107 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M7994 | PRIMA-1 | p53 |
| PRIMA-1 is a selective re-activator of mutant p53 activity in tumor cells, and an inducer of apoptosis and inhibitor of growth of human tumors with mutant p53. | ||
| M9623 | APR-246 (Eprenetapopt) | p53 |
| PRIMA-1MET; Eprenetapopt | ||
| APR-246 (Eprenetapopt) is the first-in-class small molecule to restore wild-type p53 function in TP53 mutant cells. APR-246 (Eprenetapopt) also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of REDOX balance in cells. | ||
| M2197 | Sulfasalazine | Ferroptosis |
| Salazopyrin；Azulfidine；Sulphasalazine; SAS | ||
| Sulfasalazine is a sulfonamide agent derived from Mesalazine. Sulfasalazine has xC-system inhibitory activity associated with iron death and is primarily used as an anti-inflammatory agent. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 ferroptosis inducer. | ||
| M3640 | BAY 57-1293 | Anti-infection |
| Pritelivir; AIC316 | ||
| BAY 57-1293 is a potent helicase primase inhibitor that exhibites antiviral effect on herpes simplex virus (HSV) with IC50 of 20 nM for both HSV-1 and HSV-2. | ||
| M5789 | Miglustat | Glucosylceramide Synthase |
| N-Butyldeoxynojirimycin; NB-DNJ; OGT918 | ||
| Miglustat(OGT918) is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1). | ||
| M7504 | CIL56 (CA3) | Ferroptosis |
| CIL56 (CA3) is a potent and selective ferroptosis inducer, it has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. | ||
| M8121 | PD-85639 | Others |
| PD-85639 (PD85,639) is a voltage-gated sodium (Na+) channel blocker (75% in 10 min & >95% in 25 min blockage of Na+ current by 25 μM PD85,639; whole-cell patch clamp using primary rat brain neurons) that is shown to target rat brain Nav1. | ||
| M8391 | Icaritin | Autophagy |
| Anhydroicaritin | ||
| Icaritin (Anhydroicaritin) is a flavonoid derivative of isoprene from Epimedium Genusis. It effectively inhibited the proliferation of K562 cells (IC50 8 µM) and primary CML cells (IC50 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3/AKT signaling and enhance osteogenesis. | ||
| M8952 | WS6 | IκB/IKK |
| WS6 is a novel beta cell proliferation simulator, which promotes β cell proliferation in rodent and human primary islets with EC50 of 0.28 uM(R7T1 cell viability). | ||
| M9303 | Amenamevir | Anti-infection |
| ASP2151 | ||
| Amenamevir is a herpes virus helicase-primase inhibitor, with an EC50 of 14 ng/mL against HSVs. | ||
| M10310 | Miglustat hydrochloride | Glucosylceramide Synthase |
| OGT 918 HCl; NB-DNJ HCl; Miglustat HCl | ||
| Miglustat hydrochloride also known as OGT 918 and NB-DNJ, inhibits glucosylceramide synthase, and is used primarily to treat Type I Gaucher disease (GD1). | ||
| M10645 | MS402 | Epigenetic Reader Domain |
| MS-402 | ||
| MS402 is a novel BD1-selective BET BrD inhibitor, inhibiting primarily Th17 cell differentiation with a little or almost no effect on Th1 or Th2 and Treg cells. MS402 has Ki values of 77 nM, 718 nM, 110 nM, 200 nM, 83 nM, and 240 nM for BRD4(BD1), BRD4(BD2), BRD3(BD1), BRD3(BD2), BRD2(BD1) and BRD2(BD2), respectively. | ||
| M10805 | Cercosporin | PKC |
| cgp049090 | ||
| Cercosporin is produced by the plant pathogenSporakikuchii and elsinochromes, pigments of the elsinoe family of fungi. Cercosporin is an effective photosensitizer with a short activation wavelength that is primarily suitable for surface PDT photodynamic studies (especially for the avoidance of perforation studies). Cercosporin contains the perylenequinone structural features necessary to PKC activity with an IC50 of 0.6-1.3 μM. | ||
| M14572 | Jagged-1 (188-204) TFA | Notch |
| Jagged-1 (188-204) TFA is a fragment of the Jagged-1 (JAG-1) protein. JAG-1 is a Notch ligand highly expressed in cultured and primary multiple myeloma (MM) cells. JAG-1 induces maturation of monocyte-derived human dendritic cells. | ||
| M20395 | Tetrabenazine (Xenazine) | Dopamine Receptor |
| Tetrabenazine(Nitoman, Xenazine) acts primarily as a reversible high-affinity inhibitor of mono-amine uptake into granular vesicles of presynaptic neurons by binding selectively to VMAT-2 Also blocks dopamine D2 receptors, but this affinity is 1,000-fold lower than its affinity for VMAT-2. | ||
| M21094 | Recombinant Rat IL-1β (E. coli) | Recombinant Proteins |
| Interleukin-1 Beta; IL1F2 | ||
| Interleukin-1β (IL-1β) is a non-secreted pro-inflammatory cytokine produced primarily by activated macrophages as well as neutrophils, epithelial cells and endothelial cells. Measured by a cell proliferation assay using mouse D10S cells, the ED50 is < 10.0 pg/ml, corresponding to a specific activity of > 1.0 × 108 units/mg. | ||
| M21341 | β-Muricholic Acid | Metabolite/Endogenous Metabolite |
| β-Muricholic acid is a murine-specific primary bile acid. Dietary administration of β-MCA reduces HMG-CoA reductase activity in liver microsomes from mice fed a high cholesterol and cholic acid diet. Dietary administration of β-MCA also dissolves 100% of gallstones in a gallstone-susceptible mouse model of diet-induced cholesterol gallstones. | ||
| M25077 | Tarlatamab | Notch |
| AMG-757 | ||
| Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research. | ||
| M25218 | Galiximab | Others |
| IDEC 114; Anti-Human CD80 Recombinant Antibody | ||
| Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. | ||
| M25426 | Recombinant Mouse SDF-1 Protein (E. coli) | Recombinant Proteins |
| Stromal cell-derived factor 1; CXCL12 | ||
| The stromal cell-derived factor-1 (SDF1), also known as CXCL12, is a small (8 kDa) cytokine highly conserved chemotactic cytokine belonging to the large family of CXC chemokines. SDF-1 binds primarily to CXC receptor 4 (CXCR4; CD184). The binding of CXCL12 to CXCR4 induces intracellular signaling through several divergent pathways initiating signals related to chemotaxis, cell survival and/or proliferation, increase in intracellular calcium, and gene transcription. | ||
| M25427 | Recombinant Human SDF-1 Protein (E. coli) | Recombinant Proteins |
| Stromal cell-derived factor-1 | ||
| The human stromal cell-derived factor-1 (SDF1), also known as CXCL12, is a small (8 kDa) cytokine highly conserved chemotactic cytokine belonging to the large family of CXC chemokines. SDF-1 binds primarily to CXC receptor 4 (CXCR4; CD184). The binding of CXCL12 to CXCR4 induces intracellular signaling through several divergent pathways initiating signals related to chemotaxis, cell survival and/or proliferation, increase in intracellular calcium, and gene transcription. | ||
| M25484 | Recombinant Human HBAZ Protein (E.coli, N-6His) | Recombinant Proteins |
| Hemoglobin Subunit Zeta | ||
| Hemoglobin Subunit Zeta (HBZ) is a member of the Globin family. The zeta chain is an alpha-type chain of mammalian embryonic Hemoglobin that is synthesized primarily in the yolk sac of the early embryo, while alpha-globin is produced throughout fetal growth and adult life. Recombinant Human Hemoglobin Subunit Zeta is produced by our E.coli expression system and the target gene encoding Met1-Arg142 is expressed with a 6His tag at the N-terminus. | ||
| M28184 | Debio 0617B | STAT |
| Debio 0617B, a multi-kinase inhibitor, reduces maintenance and self-renewal of primary human AML CD34+ stem/progenitor cells. Debio 0617B has a unique profile targeting key kinases upstream of STAT3/STAT5 signaling such as JAK, SRC, ABL, and class III/V receptor tyrosine kinases (TKs). Debio 0617B has documented efficacy in STAT3-driven solid tumors. | ||
| M28401 | AMY-101 | Complement System |
| Cp40 | ||
| AMY-101 (Cp40), a peptidic inhibitor of the central complement component C3 (KD = 0.5 nM), inhibits naturally occurring periodontitis in non-human primates (NHPs). AMY-101 (Cp40) exhibits a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation. | ||
| M28405 | Pritelivir mesylate hydrate | Anti-infection |
| AIC316 mesylate hydrate; BAY 57-1293 mesylate hydrate | ||
| Pritelivir mesylate hydrate (BAY 57-1293 mesylate hydrate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate hydrate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2. | ||
| M28406 | Pritelivir mesylate | Anti-infection |
| AIC316 mesylate; BAY 57-1293 mesylate | ||
| Pritelivir mesylate (BAY 57-1293 mesylate), an inhibitor of the viral helicase-primase complex, exhibits antiviral activity in vitro and in animal models of herpes simplex virus (HSV) infection. Pritelivir mesylate is active against herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) with the IC50 of 0.02 μM against HSV1-2. | ||
| M28438 | L685818 | Antifungal |
| L685818 is a specific immunophilin ligand. L685818 was neuroregenerative and non-neuroprotective in primary brain cultures. L685818 protects dopaminergic neurons from toxic inhibition of MPP+ and 6-OHDA, reduces tyrosine hydroxylase (TH) loss, and promotes neuronal process regeneration. L685818 is also an antifungal reagent for Cryptococcus neoformans. | ||
| M28482 | NaPi2b-IN-1 | Others |
| NaPi2b-IN-1 is a potent and orally active inhibitor of sodium-dependent phosphate transport protein 2b (NaPi2b) with an IC50 of 64 nM. NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. NaPi2b-IN-1 has the potential for the research of hyperphosphatemia. | ||
| M28721 | Sofpironium bromide | AChR/AChE |
| BBI 4000 | ||
| Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes. | ||
| M29900 | ICA-105574 | Potassium Channel |
| ICA-105574 is a potent and efficacious hERG channel activator. The primary mechanism by which ICA-105574 potentiates hERG channel activity is by removing hERG channel inactivation. ICA-105574 steeply potentiates current amplitudes more than 10-fold with an EC50 value of 0.5 +/- 0.1 μM and a Hill slope (n(H)) of 3.3 +/- 0.2. | ||
| M40954 | Lumasiran | Others |
| ALN-G01 | ||
| Lumasiran is a siRNA compound that reduces hepatic oxalate production by targeting ethanoic acid oxidase. It can be used in studies related to primary hyperoxaluria type 1 (PH1). | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
